1,597
Participants
Start Date
September 30, 2005
Primary Completion Date
January 31, 2006
Study Completion Date
February 28, 2006
Trivalent inactivated influenza vaccine
A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
Trivalent inactivated influenza vaccine
A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
Trivalent inactivated influenza vaccine
A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
University of Maryland Baltimore, Baltimore
Duke Health Center, Durham
Vanderbilt University, Nashville
Saint Louis University, St Louis
Baylor College of Medicine, Houston
UCLA Center For Vaccine Research, Torrance
Stanford University School of Medicine, Stanford
University of Iowa - Vaccine Research & Education Unit, Iowa City
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases, Rochester
Cincinnati Children's Hospital Medical Center, Cincinnati
National Institute of Allergy and Infectious Diseases (NIAID)
NIH